{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:56:06Z","timestamp":1782968166782,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Huangkui Lianchang Decoction (HLD) is a traditional Chinese herbal formula for treating ulcerative colitis (UC). However, its mechanism of action remains poorly understood. The Study aims to validate the therapeutic effect of HLD on UC and its mechanism by integrating network pharmacology, bioinformatics, and experimental validation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>UC targets were collected by databases and GSE19101. The active ingredients in HLD were detected by ultra-performance liquid chromatography-tandem mass spectrometry. PubChem collected targets of active ingredients. Protein\u2013protein interaction (PPI) networks were established with UC-related targets. Gene Ontology and Kyoto Encyclopedia (KEGG) of Genes and Genomes enrichment were analyzed for the mechanism of HLD treatment of UC and validated by the signaling pathways of HLD. Effects of HLD on UC were verified using dextran sulfate sodium (DDS)-induced UC mice experiments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1883 UC-related targets were obtained from the GSE10191 dataset, 1589 from the database, and 1313 matching HLD-related targets, for a total of 94 key targets. Combined with PPI, GO, and KEGG network analyses, the signaling pathways were enriched to obtain IL-17, Toll-like receptor, NF-\u03baB, and tumor necrosis factor signaling pathways. In animal experiments, HLD improved the inflammatory response of UC and reduced UC-induced pro-inflammatory factors such as Tumor Necrosis Factor Alpha (TNF-\u03b1), interleukin 1\u03b2 (IL-1\u03b2), and interleukin 6 (IL-6). HLD suppressed proteins TLR4, MyD88, and NF-\u03baB expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study systematically dissected the molecular mechanism of HLD for the treatment of UC using a network pharmacology approach. Further animal verification experiments revealed that HLD inhibited inflammatory responses and improved intestinal barrier function through the TLR4\/MyD88\/NF-\u03baB pathway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-024-04590-3","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:03:50Z","timestamp":1721754230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrated network pharmacology and bioinformatics to identify therapeutic targets and molecular mechanisms of Huangkui Lianchang Decoction for ulcerative colitis treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Zongqi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bensheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"4590_CR1","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851.","journal-title":"Dis Mon"},{"key":"4590_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"4590_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17474124.2021.1840976","volume":"15","author":"S-C Wei","year":"2021","unstructured":"Wei S-C, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ, et al. Epidemiology, the burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Rev Gastroenterol Hepatol. 2021;15:275\u201389.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4590_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/17474124.2018.1503052","volume":"12","author":"AI Sharara","year":"2018","unstructured":"Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L, et al. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. Expert Rev Gastroenterol Hepatol. 2018;12:883\u201397.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4590_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.121.000904","volume":"380","author":"D Tus\u00e9","year":"2022","unstructured":"Tus\u00e9 D, Reeves M, Royal J, Hamorsky KT, Ng H, Arolfo M, et al. Pharmacokinetics and safety studies in rodent models support development of EPICERTIN as a novel topical wound-healing biologic for ulcerative colitis. J Pharmacol Exp Ther. 2022;380:162\u201370.","journal-title":"J Pharmacol Exp Ther"},{"key":"4590_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000444217","volume":"93","author":"S Sugimoto","year":"2016","unstructured":"Sugimoto S, Naganuma M, Kiyohara H, Arai M, Ono K, Mori K, et al. Clinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study. Digestion. 2016;93:193\u2013201.","journal-title":"Digestion"},{"key":"4590_CR7","doi-asserted-by":"publisher","first-page":"e21903","DOI":"10.1097\/MD.0000000000021903","volume":"99","author":"F-S Kou","year":"2020","unstructured":"Kou F-S, Shi L, Li J-X, Wang Z-B, Shi R, Mao T-Y, et al. Clinical evaluation of traditional Chinese medicine on mild active ulcerative colitis: a multi-center, randomized, double-blind, controlled trial. Medicine (Baltimore). 2020;99:e21903.","journal-title":"Medicine (Baltimore)"},{"key":"4590_CR8","doi-asserted-by":"publisher","first-page":"e6651","DOI":"10.1097\/MD.0000000000006651","volume":"96","author":"Y-C Dai","year":"2017","unstructured":"Dai Y-C, Zheng L, Zhang Y-L, Chen X, Chen D-L, Tang Z-P. Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: a randomized controlled trial. Medicine. 2017;96:e6651.","journal-title":"Medicine"},{"key":"4590_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13063-020-04315-0","volume":"21","author":"Y Chen","year":"2020","unstructured":"Chen Y, Deng J, Wen Y, Chen B, Hou J, Peng B, et al. Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials. Trials. 2020;21:396.","journal-title":"Trials"},{"key":"4590_CR10","doi-asserted-by":"publisher","first-page":"111580","DOI":"10.1016\/j.biopha.2021.111580","volume":"139","author":"H Shen","year":"2021","unstructured":"Shen H, Zhang S, Zhao W, Ren S, Ke X, Gu Q, et al. Randomised clinical trial: efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. Biomed Pharmacother. 2021;139:111580.","journal-title":"Biomed Pharmacother"},{"key":"4590_CR11","first-page":"833","volume":"41","author":"Z He","year":"2019","unstructured":"He Z, Wu B, Wen K, Sun X, Wang X, Zhang C. Clinical observation of Huangkui Lianchang prescription enema in the treatment of distal ulcerative colitis. Hebei J Tradit Chin Med. 2019;41:833\u20137+843.","journal-title":"Hebei J Tradit Chin Med"},{"key":"4590_CR12","first-page":"75","volume":"49","author":"H Liu","year":"2022","unstructured":"Liu H, Zhou Q, Wang B, Duan Z, Shi G, Jiang F, et al. Retrospective analysis of the efficacy of Huangkui Lianyang Prescription in the Treatment of 101 cases of mild to moderately active ulcerative colitis. Liaoning J Tradit Chin Med. 2022;49:75\u20137.","journal-title":"Liaoning J Tradit Chin Med"},{"key":"4590_CR13","doi-asserted-by":"publisher","first-page":"1040847","DOI":"10.1155\/2019\/1040847","volume":"2019","author":"Z He","year":"2019","unstructured":"He Z, Zhou Q, Wen K, Wu B, Sun X, Wang X, et al. Huangkui Lianchang Decoction ameliorates DSS-induced ulcerative colitis in mice by inhibiting the NF-kappaB signaling pathway. Evid Based Complement Alternat Med. 2019;2019:1040847.","journal-title":"Evid Based Complement Alternat Med"},{"key":"4590_CR14","doi-asserted-by":"publisher","first-page":"951558","DOI":"10.3389\/fphar.2022.951558","volume":"13","author":"X Cheng","year":"2022","unstructured":"Cheng X, Du J, Zhou Q, Wu B, Wang H, Xu Z, et al. Huangkui lianchang decoction attenuates experimental colitis by inhibiting the NF-\u03baB pathway and autophagy. Front Pharmacol. 2022;13:951558.","journal-title":"Front Pharmacol"},{"key":"4590_CR15","doi-asserted-by":"publisher","first-page":"115835","DOI":"10.1016\/j.jep.2022.115835","volume":"301","author":"Y Ma","year":"2023","unstructured":"Ma Y, Hu J, Song C, Li P, Cheng Y, Wang Y, et al. Er-Xian decoction attenuates ovariectomy-induced osteoporosis by modulating fatty acid metabolism and IGF1\/PI3K\/AKT signaling pathway. J Ethnopharmacol. 2023;301:115835.","journal-title":"J Ethnopharmacol"},{"key":"4590_CR16","doi-asserted-by":"publisher","first-page":"114321","DOI":"10.1016\/j.jep.2021.114321","volume":"281","author":"P-Y Chen","year":"2021","unstructured":"Chen P-Y, Yuan C, Hong Z-C, Zhang Y, Ke X-G, Yu B, et al. Revealing the mechanism of \u201cHuai Hua San\u201d in the treatment of ulcerative colitis based on network pharmacology and experimental study. J Ethnopharmacol. 2021;281:114321.","journal-title":"J Ethnopharmacol"},{"key":"4590_CR17","doi-asserted-by":"publisher","first-page":"154658","DOI":"10.1016\/j.phymed.2023.154658","volume":"111","author":"Z-L Duan","year":"2023","unstructured":"Duan Z-L, Wang Y-J, Lu Z-H, Tian L, Xia Z-Q, Wang K-L, et al. Wumei Wan attenuates angiogenesis and inflammation by modulating RAGE signaling pathway in IBD: network pharmacology analysis and experimental evidence. Phytomedicine. 2023;111:154658.","journal-title":"Phytomedicine"},{"key":"4590_CR18","doi-asserted-by":"publisher","first-page":"bbad027","DOI":"10.1093\/bib\/bbad027","volume":"24","author":"S Tian","year":"2023","unstructured":"Tian S, Zhang J, Yuan S, Wang Q, Lv C, Wang J, et al. Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM. Brief Bioinform. 2023;24:bbad027.","journal-title":"Brief Bioinform."},{"key":"4590_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nprot.2017.044","volume":"12","author":"S Wirtz","year":"2017","unstructured":"Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295\u2013309.","journal-title":"Nat Protoc"},{"key":"4590_CR20","doi-asserted-by":"crossref","unstructured":"Jauregui-Amezaga A, Geerits A, Das Y, Lemmens B, Sagaert X, Bessissow T, et al. A simplified geboes score for ulcerative colitis. J Crohns Colitis. 2017;11:305\u201313.","DOI":"10.1093\/ecco-jcc\/jjw154"},{"key":"4590_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41598-021-03980-8","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Liu X, Li G. Integrated bioinformatics and network pharmacology to identify the therapeutic target and molecular mechanisms of Huangqin decoction on ulcerative Colitis. Sci Rep. 2022;12:159.","journal-title":"Sci Rep"},{"key":"4590_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/nbt1007-1110","volume":"25","author":"AL Hopkins","year":"2007","unstructured":"Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25:1110\u20131.","journal-title":"Nat Biotechnol"},{"key":"4590_CR23","doi-asserted-by":"publisher","first-page":"115647","DOI":"10.1016\/j.jep.2022.115647","volume":"298","author":"W Yu","year":"2022","unstructured":"Yu W, Liang Z, Li Q, Liu Y, Liu X, Jiang L, et al. The pharmacological validation of the Xiao-Jian-Zhong formula against ulcerative colitis by network pharmacology integrated with metabolomics. J Ethnopharmacol. 2022;298:115647.","journal-title":"J Ethnopharmacol"},{"key":"4590_CR24","doi-asserted-by":"publisher","first-page":"bbad346","DOI":"10.1093\/bib\/bbad346","volume":"24","author":"S Tian","year":"2023","unstructured":"Tian S, Li Y, Xu J, Zhang L, Zhang J, Lu J, et al. COIMMR: a computational framework to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming. Brief Bioinform. 2023;24:bbad346.","journal-title":"Brief Bioinform."},{"key":"4590_CR25","doi-asserted-by":"publisher","first-page":"eabb4432","DOI":"10.1126\/sciimmunol.abb4432","volume":"5","author":"BS Boland","year":"2020","unstructured":"Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020;5:eabb4432.","journal-title":"Sci Immunol."},{"key":"4590_CR26","doi-asserted-by":"publisher","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","volume":"21","author":"H Nakase","year":"2022","unstructured":"Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21:103017.","journal-title":"Autoimmun Rev"},{"key":"4590_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-med-052919-120048","volume":"72","author":"RP Hirten","year":"2021","unstructured":"Hirten RP, Sands BE. New Therapeutics for ulcerative colitis. Annu Rev Med. 2021;72:199\u2013213.","journal-title":"Annu Rev Med"},{"key":"4590_CR28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"4590_CR29","doi-asserted-by":"publisher","first-page":"111427","DOI":"10.1016\/j.biopha.2021.111427","volume":"138","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, et al. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother. 2021;138:111427.","journal-title":"Biomed Pharmacother"},{"key":"4590_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1017\/S0954422416000019","volume":"29","author":"WM Miner-Williams","year":"2016","unstructured":"Miner-Williams WM, Moughan PJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. Nutr Res Rev. 2016;29:40\u201359.","journal-title":"Nutr Res Rev"},{"key":"4590_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-\u03b3: teammate or opponent in the tumor microenvironment? Nat Rev Immunol. 2022;22:158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"4590_CR32","doi-asserted-by":"publisher","first-page":"674416","DOI":"10.3389\/fphar.2021.674416","volume":"12","author":"Q Yang","year":"2021","unstructured":"Yang Q, Ma L, Zhang C, Lin J, Han L, He Y, et al. Exploring the mechanism of indigo naturalis in the treatment of ulcerative colitis based on TLR4\/MyD88\/NF-\u03baB signaling pathway and gut microbiota. Front Pharmacol. 2021;12:674416.","journal-title":"Front Pharmacol"},{"key":"4590_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10787-018-0523-8","volume":"27","author":"M Chamanara","year":"2019","unstructured":"Chamanara M, Rashidian A, Mehr SE, Dehpour A-R, Shirkohi R, Akbarian R, et al. Melatonin ameliorates TNBS-induced colitis in rats through the melatonin receptors: involvement of TLR4\/MyD88\/NF-\u03baB signaling pathway. Inflammopharmacol. 2019;27:361\u201371.","journal-title":"Inflammopharmacol"},{"key":"4590_CR34","doi-asserted-by":"publisher","first-page":"551449","DOI":"10.3389\/fimmu.2020.551449","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Yang S, Lun J, Gao J, Gao X, Gong Z, et al. Inhibitory effects of the lactobacillus rhamnosus GG effector protein HM0539 on inflammatory response through the TLR4\/MyD88\/NF-\u043aB Axis. Front Immunol. 2020;11:551449.","journal-title":"Front Immunol"},{"key":"4590_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-022-00925-z","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7:78.","journal-title":"Signal Transduct Target Ther"},{"key":"4590_CR36","doi-asserted-by":"publisher","first-page":"153631","DOI":"10.1016\/j.phymed.2021.153631","volume":"90","author":"C Li","year":"2021","unstructured":"Li C, Dong N, Wu B, Mo Z, Xie J, Lu Q. Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice. Phytomedicine. 2021;90:153631.","journal-title":"Phytomedicine"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-024-04590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-024-04590-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-024-04590-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:04:55Z","timestamp":1721754295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-024-04590-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4590"],"URL":"https:\/\/doi.org\/10.1186\/s12906-024-04590-3","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experimental procedures conformed to animal ethics requirements and were approved by the Experimental Animal Ethics Committee of Suzhou TCM Hospital, under Grant No. 2020 Ethical Animal Approval 002. The study was conducted by the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2020\/63\/EU in Europe to protect the experimental animals. The study followed the ARRIVE guidelines 2.0 for design, analysis, and reporting. The anesthesia and euthanasia methods we used during the experiment were referenced from the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}